Simon Shen

We are hiring postdocs. If you are passionate about using iPSC, CRISPR screens, organoids, and multiomics to understand cardiovascular disease and advance precision medicine.

Peer review was supposed to be science’s quality filter, but somewhere along the way it started acting more like a bouncer who only lets in the regulars. It’s slow, it tends to favor established labs and familiar names, and it gets uncomfortable around anything too unconventional. Papers loaded with mountains of data tend to cruise through, while bold ideas that actually challenge the consensus get stuck in limbo or turned away at the door. The irony is that where a paper gets published almost never determines its real worth. What actually matters is what the scientific community does with it afterward, whether people cite it, argue with it, build on it, or use it to blow up a long-held assumption. That’s where the value lives, not in the journal’s logo. A major survey a few years back found that roughly 70% of researchers think the current system is fundamentally broken, and it’s not hard to see why. Publicly funded research hides behind paywalls, editors chase whatever topic is hot that month, and the whole incentive structure pushes toward safe bets over genuinely risky and potentially important work. Science has always been complicated and deeply human and full of ego and inertia, but the conversation is shifting.

We have two postdoc positions available in the lab. Please refer to the link below for application details if you are interested wustl.wd1.myworkdayjobs.com/en-US/External…

We are hiring postdocs. If you are passionate about using iPSC, CRISPR screens, organoids, and multiomics to understand cardiovascular disease and advance precision medicine.

I’m thrilled to share that my new lab at the University of Chicago is recruiting postdocs! 🧠🧬 We study how somatic mutations and genomic damage drive brain aging and neurodegenerative disease, combining single-cell genomics, duplex sequencing, long-read repeat expansion sequencing, and spatial omics. Start date: July 2026 (flexible) 📩 zinan.zhou@gmail.com Would really really appreciate any RTs/shares!

My lab at MSKCC in New York is hiring for two positions. Join us at the frontier of functional genomics, studying fibroblast state transitions, combinatorial genetics, and ECM in disease. Please share with anyone who might be a good fit! (Mustache not required.)

We're partnering with @AnthropicAI on the development of artificial intelligence tools for massive data analysis and exploration. This collaboration will explore how AI systems could expedite analysis and day-to-day scientific workflows. anthropic.com/news/anthropic…

@YangEricLi @AlexsLemonade big congrats

So proud to have received generous support from @AlexsLemonade foundation🍋! We are dedicated to advance our understanding of aggressive pediatric brain tumors! 🧠🔬

@SaligramaLab Big congrats!

#NOA is in #today from #NIH. We are very much looking for #postdocs with expertise in #TCR #molecular #biology #protein #engineering #autoimmunity

My lab is looking to recruit postdoctoral scholars over multiple projects including combinatorial expression perturbations for cell state engineering, and modeling and perturbing human tissue development with tractable human organoid systems (primarily heart and brain)

There's never been a better time to come to Canada for a PhD, postdoc, or faculty position. The first part of the $1 billion+ investments is already showing up as additional funding for PhD/postdocs: nserc-crsng.canada.ca/en/news/launch…

PRSNet-2: End-to-end genotype-to-phenotype prediction via hierarchical graph neural networks biorxiv.org/content/10.110… #biorxiv_genetic

Our lab is hiring a Research Scientist available immediately to drive work on a large multi-institution project focused on liver tissue eng! Candidates with extensive hands-on experience with iPSCs & cell manufacturing expertise are encouraged to apply. lnkd.in/eTQM-8TJ

Kudos to Ali Javaheri, MD, PhD, on research that identified a type of immunotherapy that prevents and treats the heart muscle damage caused by doxorubicin, based on findings in human heart tissue, cell lines & mouse models of heart failure. Learn more > internalmedicine.wustl.edu/immunotherapy-…

Congratulations to Michael Meers, Janet Sorrells and Andrew Young, recipients of NIH Director’s High-Risk, High-Reward awards recognizing innovative approaches to today’s biggest biomedical challenges. 👏 bit.ly/4n3XmXq

Happy First Day, WashU! ❤️🐻💚

@ricomnl @anshulkundaje i am happy to test it

@anshulkundaje i agree! we're thinking about ways that can enable others to test our factors more broadly - if that doesn't materialize in the coming weeks I'll reach out

super excited to announce our collaboration to the world! here’s the backstory: we started with a shared goal of using AI to generate novel discoveries that would be non-trivial for human scientists to make

Single-nucleus RNA-seq reveals CD47 as a key driver of doxorubicin cardiomyopathy. Blocking CD47 protects the heart—offering a new therapeutic path. 🫀🧬@SDPrabhuMD @AartiAsnaniMD @BKopeckyMDPhD @twinsmc18 @AhmedAADiab @carmenbergom @Alicardsdoc ahajournals.org/doi/full/10.11…

Welcome Home, #WashU29 ! Happy Move-In Weekend! ❤️🐻💚

For PhD students in my network, @nvidia is now accepting applications for our graduate fellowship program. If you are working on topics across AI, life sciences, healthcare and HPC - consider applying. blogs.nvidia.com/blog/applicati…

@saizhang0 @xiaotaoshen1990 @NatureBiotech it is very interesting to see cardiac pericytes playing a big role in cardiomyopathy.

Excited to share that scPRS is now out @NatureBiotech! We developed a new single-cell-resolved #PRS using deep learning. nature.com/articles/s4158…

Thoughtful editorial perspective by Ebin Johny and @ParthaDuttaLab on the importance of the spleen in healing the heart after myocardial infarction. #cardiosplenic axis! Circulation ahajournals.org/doi/full/10.11…